Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing our Orexin Receptor 2 Agonist Program to bring potentially transformative treatment options to patients with sleep-wake, neurological, neurodegenerative and psychiatric disorders.
Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing our LockBody® Technology Platform with the aim to redefine immuno-oncology treatment for patients with cancer.
We are leaders, innovators, and scientists aiming to pursue medicines that are transformational for patients.
Latest News
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)